Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00964236 · ClinicalTrials.gov registry record
The Effects of Kuvan on Functional Brain Connectivity in Individuals With Phenylketonuria (PKU)
A clinical trial, sponsored by University of Missouri-Columbia.
- Completed
- Registry status
- 20
- Enrollment target
NCT00964236: Completed study, sponsored by University of Missouri-Columbia.
NCT00964236 is a clinical trial that has completed, run by University of Missouri-Columbia. The registered enrollment target is 20 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00964236 has completed, sponsored by University of Missouri-Columbia.
- COMPLETED
- Registry status
- 20 participants
- Enrollment target
Study Summary
The objective of the study is to determine whether Kuvan™ (sapropterin) improves the strength of the functional connectivity between brain regions in individuals with PKU.
Interventions
- DRUG Sapropterin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2009-08 |
| Est. Completion | 2011-08 |
What the finished NCT00964236 record still lists
NCT00964236 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 20 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Sapropterin is the first listed.
NCT00964236 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00964236 about?
NCT00964236 is a clinical study titled "The Effects of Kuvan on Functional Brain Connectivity in Individuals With Phenylketonuria (PKU)". The objective of the study is to determine whether Kuvan™ (sapropterin) improves the strength of the functional connectivity between brain regions in individuals with PKU.
What is the current status of trial NCT00964236?
This trial is currently completed. The enrollment target is 20 participants. The study started on 2009-08. Estimated completion is 2011-08.
What interventions are being tested in trial NCT00964236?
The interventions under investigation include: Sapropterin (DRUG).
Who is sponsoring clinical trial NCT00964236?
This trial is sponsored by University of Missouri-Columbia, which has 291 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia